G. Fraser Et Al. , "IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY," 21st Congress of the European-Hematology-Association , vol.101, Copenhagen, Denmark, pp.150-151, 2016
Fraser, G. Et Al. 2016. IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. 21st Congress of the European-Hematology-Association , (Copenhagen, Denmark), 150-151.
Fraser, G., Cramer, P., DEMİRKAN, F., Santucci Silva, R., Grosicki, S., Janssens, A., ... Mayer, J.(2016). IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY . 21st Congress of the European-Hematology-Association (pp.150-151). Copenhagen, Denmark
Fraser, G. Et Al. "IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY," 21st Congress of the European-Hematology-Association, Copenhagen, Denmark, 2016
Fraser, G. Et Al. "IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY." 21st Congress of the European-Hematology-Association , Copenhagen, Denmark, pp.150-151, 2016
Fraser, G. Et Al. (2016) . "IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY." 21st Congress of the European-Hematology-Association , Copenhagen, Denmark, pp.150-151.
@conferencepaper{conferencepaper, author={G. Fraser Et Al. }, title={IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY}, congress name={21st Congress of the European-Hematology-Association}, city={Copenhagen}, country={Denmark}, year={2016}, pages={150-151} }